PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026

All the vital news, analysis, and commentary curated by our industry experts.

$10995

Buy Report View Sample

Published: August 31, 2017 Report Code: GDHC153PIDR-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Migraine is a complex neurological condition, characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances. The market is currently split into acute and preventative segments, with the majority of drugs used in treatment genericized across the 7MM (US, France, Germany, Italy, Spain, UK, Japan). The current migraine treatment landscape is mainly dominated by generic drugs, as the majority of migraine drugs have seen their patents expire. Pharmacological treatment is commonly segmented into two groups, acute (abortive) and preventative (prophylaxis) treatment.

GlobalData estimates that drug sales for migraine in 2016 were approximately $3.3 billion across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.7 billion at a CAGR of 10.3%. This growth will be driven by the launch of seven late-stage pipeline products. These seven drugs can be split into three classes; CGRP monoclonal antibodies, gepants and ditans, which all have a novel mechanism of action and are expected to address significant unmet needs in the migraine market.

Scope

Overview of migraine, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (episodic, chronic), forecast from 2016 to 2026.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the migraine therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine therapy. The most promising candidates in Phase III development are profiled.

Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global migraine therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global migraine therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Pfizer
Amgen
Eli Lilly
Teva
Alder Biopharmaceuticals
Merck & Co
Allergan
Zogenix
RedHill BioPharma
OptiNose
Supernus Pharmaceuticals
GlaxoSmithKline
SUDA
Kyorin
Eisai
Pozen
Par Pharmaceuticals
Pernix Therapeutics
Endo Pharmaceuticals
Desitin
IntelGenx
Grupe JUSTE
Grunenthal
Almirall
Aspen Japan KK
Elan Pharmaceuticals
Menarini
Vernalis
AZ
MedPointe
Impax Laboratories
Pharmacia Coporation
Mallinckrodt
Janssen
AbbVie
CoLuicd
Rinat
Labrys Biologics
Arteaus Therapeutics
Novartis
NeurAxon Pharma
Curtis AG
Promius Pharma
Achelios Therapeutics
TrioxBio
Trigmina
Biohaven Pharmaceutical
Biofrontera
Ionis Pharmaceuticals

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Migraine: Executive Summary

2.1 Migraine Market Will Grow to $8.7 Billion by 2026

2.2 Companies Often Target the Underserved Migraine Population

2.3 Current Treatments Leave Major Unmet Needs in the Migraine Market

2.4 Market Opportunities for New Entrants

2.5 Late-Stage Pipeline Drugs Will Be a Key Driver in the Migraine Market

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Migraine Classification

4.2 Etiology and Pathophysiology

4.2.1 Etiology

4.2.2 Pathophysiology

4.3 Symptoms

4.3.1 Premonitory Phase

4.3.2 Aura Phase

4.3.3 Headache Phase

4.3.4 Resolution Phase

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Migraine (2016–2026)

5.5.1 Total Prevalent Cases of Migraine

5.5.2 Age-Specific Total Prevalent Cases of Migraine

5.5.3 Sex-Specific Total Prevalent Cases of Migraine

5.5.4 Migraine Cases by Frequency of Occurrences

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.2.3 Episodic Migraine

6.2.4 Chronic Migraine

6.2.5 Non-pharmacological Treatments

6.3 US

6.4 5EU

6.5 Japan

7 Competitive Assessment

7.1 Overview

7.1.1 Maxalt (rizatriptan benzoate)

7.1.2 Relpax (eletriptan hydrobromide)

7.1.3 Treximet (sumatriptan succinate + sodium naproxen)

7.1.4 Sumavel DosePro (sumatriptan succinate)

7.1.5 Rizaport (rizatriptan benzoate)

7.1.6 Onzetra Xsail (sumatriptan succinate)

7.1.7 Other Triptans

7.1.8 Botox (onabotulinum toxin A)

7.1.9 Antidepressants

7.1.10 Anti-epileptics

7.1.11 Other Therapeutic Classes

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Lack of Acute Therapies for Patients Unresponsive to Triptan Medication

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Physician Education and Diagnosis

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Effective and Well-Tolerated Prophylactic Treatments

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Country and Class

9.3 Promising Drugs in Clinical Development

9.3.1 Lasmiditan (COL-144)

9.3.2 Eptinezumab (ALD-403)

9.3.3 Fremanezumab (TEV-48125)

9.3.4 Galcanezumab (LY2951742)

9.3.5 Erenumab (AMG-334)

9.3.6 Ubrogepant (MK-1602)

9.3.7 Atogepant (AGN241689)

9.3.8 SUD-001

9.4 Promising Drugs in Early-Stage Development

9.5 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 GlaxoSmithKline

10.3.1 Overview

10.3.2 Portfolio Assessment

10.3.3 SWOT Analysis

10.4 Merck & Co.

10.4.1 Overview

10.4.2 Portfolio Assessment

10.4.3 SWOT Analysis

10.5 Pfizer

10.5.1 Overview

10.5.2 Portfolio Assessment

10.5.3 SWOT Analysis

10.6 Allergan

10.6.1 Overview

10.6.2 Portfolio Assessment

10.6.3 SWOT Analysis

10.7 Amgen

10.7.1 Overview

10.7.2 Portfolio Assessment

10.7.3 SWOT Analysis

10.8 Eli Lilly

10.8.1 Overview

10.8.2 Portfolio Assessment

10.8.3 SWOT Analysis

10.9 Alder Biopharmaceuticals

10.9.1 Overview

10.9.2 Portfolio Assessment

10.9.3 SWOT Analysis

10.10 Teva

10.10.1 Overview

10.10.2 Portfolio Assessment

10.10.3 SWOT Analysis

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Migraine Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: Migraine: Key Metrics in the 7MM

Table 2: Migraine Classification from the ICHD-3

Table 3: Diagnostic Criteria for Migraine with Aura

Table 4: Diagnostic Criteria for Migraine without Aura

Table 5: Risk Factors and Comorbidities for Migraine

Table 6: ICHD-3 Diagnostic Criteria for Migraine

Table 7: Total Prevalent Cases of Migraine, Ages ≥18 Years, Both Sexes, N, Select Years 2016–2026

Table 8: Treatment Guidelines for Migraine

Table 9: Most Prescribed Drugs for Migraine by Class in the 7MM, 2016

Table 10: Country Profile – US

Table 11: Country Profile – 5EU

Table 12: Country Profile – Japan

Table 13: Product Profile – Maxalt

Table 14: Maxalt SWOT Analysis, 2017

Table 15: Product Profile – Relpax

Table 16: Relpax Efficacy Clinical Trial Results

Table 17: Percentage of Patients with Headache Response (Mild or No Headache) 2 Hours Following Treatment

Table 18: Relpax SWOT Analysis, 2017

Table 19: Product Profile – Treximet

Table 20: Treximet SWOT Analysis, 2017

Table 21: Product Profile – Sumavel DosePro

Table 22: Sumavel DosePro SWOT Analysis, 2017

Table 23: Product Profile – Rizaport

Table 24: Rizaport SWOT Analysis, 2017

Table 25: Product Profile – Onzetra Xsail

Table 26: Onzetra Xsail SWOT Analysis, 2017

Table 27: Product Profile – Other Triptans

Table 28: Triptan SWOT Analysis, 2017

Table 29: Product Profile – Botox

Table 30: Botox SWOT Analysis, 2017

Table 31: Product Profiles – Antidepressants

Table 32: Antidepressants SWOT Analysis, 2017

Table 33: Product Profiles – Anti-epileptics

Table 34: Anti-epileptics SWOT Analysis, 2017

Table 35: Product Profile – Other Therapeutic Classes

Table 36: Unmet Need and Opportunity in Episodic and Chronic Migraine, 2017

Table 37: Migraine Late-Stage Pipeline, 2017

Table 38: Comparison of Therapeutic Classes in Development for Migraine, 2016–2026

Table 39: Product Profile – Lasmiditan

Table 40: Lasmiditan SWOT Analysis, 2017

Table 41: Product Profile – Eptinezumab (ALD-403)

Table 42: Eptinezumab (ALD-403) SWOT Analysis, 2017

Table 43: Product Profile – Fremanezumab (TEV-48125)

Table 44: Fremanezumab (TEV-48125) SWOT Analysis, 2017

Table 45: Product Profile – Galcanezumab (LY2951742)

Table 46: Product Profile – Erenumab (AMG-334)

Table 47: Erenumab (AMG-334) SWOT Analysis, 2017

Table 48: Product Profile – Ubrogepant (MK-1602)

Table 49: Ubrogepant (MK-1602) SWOT Analysis, 2017

Table 50: Product Profile – Atogepant (AGN241689)

Table 51: Atogepant (AGN241689) SWOT Analysis, 2017

Table 52: Product Profile – SUD-001

Table 53: SUD-001 SWOT Analysis, 2017

Table 54: Drugs in Development for Migraine, 2016

Table 55: Key Companies in the Migraine Market in the 7MM, 2016

Table 56: GlaxoSmithKline Disease Portfolio Assessment, 2017

Table 57: GSK SWOT Analysis, 2017

Table 58: Merck’s Disease Portfolio Assessment, 2017

Table 59: Merck SWOT Analysis, 2017

Table 60: Pfizer’s Disease Portfolio Assessment, 2017

Table 61: Pfizer SWOT Analysis, 2017

Table 62: Allergan’s Disease Portfolio Assessment, 2017

Table 63: Allergan SWOT Analysis, 2017

Table 64: Amgen’s Disease Portfolio Assessment, 2017

Table 65: Amgen SWOT Analysis, 2017

Table 66: Eli Lilly’s Disease Portfolio Assessment, 2017

Table 67: Eli Lilly SWOT Analysis, 2017

Table 68: Alder’s Disease Portfolio Assessment, 2017

Table 69: Alder SWOT Analysis, 2017

Table 70: Teva’s Disease Portfolio Assessment, 2017

Table 71: Teva SWOT Analysis, 2017

Table 72: Migraine Market – Global Drivers and Barriers, 2016–2026

Table 73: Key Events Impacting Sales for Migraine in the US, 2016–2026

Table 74: Migraine Market – Global Drivers and Barriers in the US, 2016–2026

Table 75: Key Events Impacting Sales for Migraine in the 5EU, 2016–2026

Table 76: Migraine Market – Global Drivers and Barriers in the 5EU, 2016–2026

Table 77: Key Events Impacting Sales for Migraine in Japan, 2016–2026

Table 78: Migraine Market – Global Drivers and Barriers in Japan, 2016–2026

Table 79: Key Historical and Projected Launch Dates for Migraine

Table 80: Key Historical and Projected Patent Expiry Dates for Migraine

Table 81: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Migraine in 2016 and 2026

Figure 2: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents Expected to be Licensed for the Treatment of Migraine During the Forecast Period

Figure 4: Pathophysiology of a Migraine

Figure 5: 7MM, Age-Standardized Total Prevalence of Migraine, Both Sexes, Ages ≥18 Years, 2016

Figure 6: Sources Used and Not Used in Epidemiological Analysis of Migraine Prevalence

Figure 7: Sources Used and Not Used in Epidemiological Analysis of Migraine Frequency

Figure 8: 7MM, Age-Specific Total Prevalent Cases of Migraine, Both Sexes, Ages ≥18 Years, 2016

Figure 9: 7MM, Sex-Specific Total Prevalent Cases of Migraine, Ages ≥18 Years, 2016

Figure 10: 7MM, Total Prevalent Migraine Cases by Frequency of Occurrences, Both Sexes, Ages ≥18 Years, 2016

Figure 11: Overview of the Development Pipeline in Migraine. Darkest circle indicates Phase III of development, the lightest circle Phase

Figure 12: Migraine Clinical Trials by Class and Country

Figure 13: Migraine Clinical Trials for Drugs in the Late-Stage Pipeline

Figure 14: A Competitive Assessment of the Late-Stage Pipeline Agents in Development for the Treatment of Migraine for 2016–2026

Figure 15: Clinical and Commercial Positioning of Lasmiditan (COL-144)

Figure 16: Clinical and Commercial Positioning of Eptinezumab (ALD-403)

Figure 17: Clinical and Commercial Positioning of Fremanezumab (TEV-48125)

Figure 18: Clinical and Commercial Positioning of Galcanezumab (LY2951742)

Figure 19: Clinical and Commercial Positioning of Erenumab (AMG-334)

Figure 20: Clinical and Commercial Positioning of Ubrogepant (MK-1602)

Figure 21: Clinical and Commercial Positioning of Atogepant (AGN241689)

Figure 22: Clinical and Commercial Positioning of SUD-001

Figure 23: Global Sales of Branded Products for Migraine by Company in 2016 and 2026

Figure 24: Analysis of the Company Portfolio Gap in Migraine During the Forecast Period

Figure 25: Global (7MM) Sales Forecast by Country for Migraine in 2016 and 2026

Figure 26: Sales Forecast by Class for Migraine in the US in 2016 and 2026

Figure 27: Sales Forecast by Class for Migraine in the 5EU in 2016 and 2026

Figure 28: Sales Forecast by Class for Migraine in Japan in 2016 and 2026

Frequently asked questions

PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026 standard reports

Currency USD

Single User

$10,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports

Pharmaceuticals

New

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…

Pharmaceuticals

New

Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…

Pharmaceuticals

New

Clinical Trials Scorecard for Investigations in 2023

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026 in real time.

Access a live PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

PharmaPoint: Migraine – Global Drug Forecast and Market Analysis to 2026

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports